Stem cell stocks, meaning cellular therapy biotech companies, face many challenges, but their clinical research is crucial. Stem cell biotechs These biotechs have ups and downs, sometimes at the same time. This is kind of the standard of “life” as any biotech company. It is definitely the case in the volatile stem cell and cell […]
24 cell therapy & stem cell stocks I’m following Read More »
Recently I was going through a list I’m updating of regenerative medicine biotech companies including Bluebird bio. Now just a few days later the world seems turned upside down for the firm and maybe to some degree for other companies doing related work. Bluebird bio blues: 2 trial participants get cancer News broke today that
Bluebird bio sickle cell gene therapy trial halted on cancer worry Read More »
I’m old enough to remember when the acronym MSC stood unambiguously for “mesenchymal stem cells”, but should it refer to a broader term like “mesenchymal cells”? The field has moved in that direction. I think that’s the best way to go too and I’ll explain why. The goal of today’s post is to help you
Mesenchymal cells or MSCs: definition, clinical potential, challenges Read More »
Induced pluripotent stem cells or iPS cells just might be the most exciting development in the stem cell field over the last 15 years. They have unique potential for clinical impact for regenerative medicine too. This may manifest both through their use to produce differentiated cellular therapies and indirectly via disease modeling as well as
What are induced pluripotent stem cells or IPS cells? Read More »
In any given field of biomedical science like stem cell research and regenerative medicine, it’s very useful if you can accurately predict the future. It seems, though, that predictions are far more difficult within the more exciting and rapidly-changing fields. The field of stem cells and regenerative medicine fits that bill. Past stem cell research
21 Stem Cell Research & Regenerative Medicine 2021 Predictions Read More »
What a year 2020 was, but there was still plenty of great science, which continues now in 2021 including published research like today’s recommended pieces and there’s one thread on MSCs today. The Niche new look, more features, and a Medical Advisory Board for 2021 Before we get to the recommended reads, note that 2021
Recommended reads: MSCs, vision, endothelial cells, more Read More »
The stem cell field has puzzled on and off for years over a constellation of papers on purported stem cells including so-called VSEL and MUSE cells. Many of us haven’t been convinced that these are real stem cells. I see VSEL and MUSE fitting into a larger pattern of dubious stem cell claims including the STAP
STAP cell deja vu? 28 VSEL papers flagged by Bik Read More »
After all this time writing on The Niche here since 2010, I still haven’t entirely resolved certain blogging dilemmas including when a patient discloses something. It’s kind of a jungle out there on the internet. What kinds of tough blogging dilemmas do I face? I’m just going to give you some examples of the more common
Stem cell blogging dilemmas: patient disclosures, lawsuits, & more Read More »
Maybe we can use science as an escape from politics during the last week or so before the election? I hope so. Here are my weekly recommended reads. Several papers ended up relating to nucleus, cell and embryo size and space as well as chromatin, which is very interesting. Cell and chromatin biology pubs, media
Weekly science reads: CRISPR, stem cells, cell size & space, more Read More »
What a difference one day can make including in the types of questions I’m getting with this one rising to the top: should President Donald Trump get stem cells for his COVID-19? Whether he should or not, will he get them? This is more than a hypothetical as a surprising number of people in Trump’s
Will Trump get stem cells for COVID-19? Read More »